01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
December 18, 2024 08:00 ET | Praxis Precision Medicines, Inc.
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
December 03, 2024 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
November 26, 2024 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
November 06, 2024 17:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 06, 2024 07:30 ET | Praxis Precision Medicines, Inc.
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
November 01, 2024 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
September 26, 2024 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
September 05, 2024 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
September 04, 2024 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
September 03, 2024 07:30 ET | Praxis Precision Medicines, Inc.
Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness,...